^
    Back
    Association details:
    Biomarker:PDGFRA D842V
    Cancer:Gastrointestinal Stromal Tumor
    Drug:dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Published date:
    10/30/2020
    Excerpt:
    Gastrointestinal Stromal Tumors: Useful in certain circumstances…Dasatinib (for patients with PDGFRA D842V mutation)…
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Med
    Title:

    A prospective multicenter phase II study on the efficacy and safety of dasatinib in the treatment of metastatic gastrointestinal stromal tumors failed by imatinib and sunitinib and analysis of NGS in peripheral blood

    Published date:
    07/17/2020
    Excerpt:
    In four patients with PDGFRA D842V mutation, two patients had SD.
    DOI:
    10.1002/cam4.3319